• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 S/MAR 的内含子与囊性纤维化跨膜电导调节因子基因的组装和功能分析。

Assembly and Functional Analysis of an S/MAR Based Episome with the Cystic Fibrosis Transmembrane Conductance Regulator Gene.

机构信息

Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, 00185 Rome, Italy.

Laboratory of Experimental and Regenerative Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.

出版信息

Int J Mol Sci. 2018 Apr 17;19(4):1220. doi: 10.3390/ijms19041220.

DOI:10.3390/ijms19041220
PMID:29673202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5979583/
Abstract

Improving the efficacy of gene therapy vectors is still an important goal toward the development of safe and efficient gene therapy treatments. S/MAR (scaffold/matrix attached region)-based vectors are maintained extra-chromosomally in numerous cell types, which is similar to viral-based vectors. Additionally, when established as an episome, they show a very high mitotic stability. In the present study we tested the idea that addition of an S/MAR element to a CFTR (cystic fibrosis transmembrane conductance regulator) expression vector, may allow the establishment of a CFTR episome in bronchial epithelial cells. Starting from the observation that the S/MAR vector pEPI-EGFP (enhanced green fluorescence protein) is maintained as an episome in human bronchial epithelial cells, we assembled the CFTR vector pBQ-S/MAR. This vector, transfected in bronchial epithelial cells with mutated , supported long term wt expression and activity, which in turn positively impacted on the assembly of tight junctions in polarized epithelial cells. Additionally, the recovery of intact pBQ-S/MAR, but not the parental vector lacking the S/MAR element, from transfected cells after extensive proliferation, strongly suggested that pBQ-S/MAR was established as an episome. These results add a new element, the S/MAR, that can be considered to improve the persistence and safety of gene therapy vectors for cystic fibrosis pulmonary disease.

摘要

提高基因治疗载体的疗效仍然是开发安全有效的基因治疗方法的一个重要目标。基于 S/MAR(支架/基质附着区)的载体在许多细胞类型中以染色体外的方式维持,这类似于基于病毒的载体。此外,当作为附加体建立时,它们表现出非常高的有丝分裂稳定性。在本研究中,我们检验了这样一种想法,即在 CFTR(囊性纤维化跨膜电导调节剂)表达载体中添加 S/MAR 元件,可能允许在支气管上皮细胞中建立 CFTR 附加体。从观察到 S/MAR 载体 pEPI-EGFP(增强型绿色荧光蛋白)以附加体的形式在人支气管上皮细胞中维持的结果出发,我们组装了 CFTR 载体 pBQ-S/MAR。该载体在突变的 转染支气管上皮细胞后,支持长期 wt 的表达和活性,这反过来又对极化上皮细胞中紧密连接的组装产生了积极影响。此外,从大量增殖后的转染细胞中回收完整的 pBQ-S/MAR,但不能回收缺乏 S/MAR 元件的亲本载体,强烈表明 pBQ-S/MAR 已作为附加体建立。这些结果增加了一个新的元素,即 S/MAR,可以被认为是提高囊性纤维化肺病基因治疗载体的持久性和安全性的一个因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/5b4d21453ddb/ijms-19-01220-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/f0eb8dcbfb7f/ijms-19-01220-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/8fd8a9d36cc4/ijms-19-01220-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/62ad0d81918a/ijms-19-01220-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/b3bfa8d83fef/ijms-19-01220-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/d47bfcd46797/ijms-19-01220-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/5b4d21453ddb/ijms-19-01220-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/f0eb8dcbfb7f/ijms-19-01220-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/8fd8a9d36cc4/ijms-19-01220-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/62ad0d81918a/ijms-19-01220-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/b3bfa8d83fef/ijms-19-01220-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/d47bfcd46797/ijms-19-01220-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/5b4d21453ddb/ijms-19-01220-g006.jpg

相似文献

1
Assembly and Functional Analysis of an S/MAR Based Episome with the Cystic Fibrosis Transmembrane Conductance Regulator Gene.基于 S/MAR 的内含子与囊性纤维化跨膜电导调节因子基因的组装和功能分析。
Int J Mol Sci. 2018 Apr 17;19(4):1220. doi: 10.3390/ijms19041220.
2
Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.囊性纤维化跨膜电导调节因子-mRNA 递呈:囊性纤维化基因治疗的新选择。
J Gene Med. 2013 Nov-Dec;15(11-12):414-26. doi: 10.1002/jgm.2748.
3
Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.腺病毒 5 型纤维 35 嵌合载体介导的囊性纤维化跨膜电导调节因子缺陷在囊性纤维化原代气道上皮中的有效顶端矫正。
Hum Gene Ther. 2010 Mar;21(3):251-69. doi: 10.1089/hum.2009.056.
4
Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells.利用重组腺相关病毒进行的剪接体介导的RNA反式剪接可部分恢复囊性纤维化跨膜传导调节因子功能至极化的人囊性纤维化气道上皮细胞。
Hum Gene Ther. 2005 Sep;16(9):1116-23. doi: 10.1089/hum.2005.16.1116.
5
Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.囊性纤维化气道中两个独立原发性缺陷的载体特异性互补图谱。
Hum Gene Ther. 1998 Mar 20;9(5):635-48. doi: 10.1089/hum.1998.9.5-635.
6
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.腺相关病毒载体-囊性纤维化跨膜传导调节因子(AAV-CFTR)在囊性纤维化上颌窦中的安全性和生物学疗效
Laryngoscope. 1999 Feb;109(2 Pt 1):266-74. doi: 10.1097/00005537-199902000-00017.
7
Gene transfer to freshly isolated human respiratory epithelial cells in vitro using a replication-deficient adenovirus containing the human cystic fibrosis transmembrane conductance regulator cDNA.使用携带人囊性纤维化跨膜传导调节因子cDNA的复制缺陷型腺病毒,在体外将基因转移至新鲜分离的人呼吸道上皮细胞。
Hum Gene Ther. 1994 Mar;5(3):331-42. doi: 10.1089/hum.1994.5.3-331.
8
Transfer of the Cystic Fibrosis Transmembrane Conductance Regulator to Human Cystic Fibrosis Cells Mediated by Extracellular Vesicles.细胞外囊泡介导囊性纤维化跨膜传导调节因子向人囊性纤维化细胞的转移。
Hum Gene Ther. 2016 Feb;27(2):166-83. doi: 10.1089/hum.2015.144.
9
Paracellular transport through healthy and cystic fibrosis bronchial epithelial cell lines--do we have a proper model?通过健康和囊性纤维化支气管上皮细胞系的细胞旁转运——我们有合适的模型吗?
PLoS One. 2014 Jun 19;9(6):e100621. doi: 10.1371/journal.pone.0100621. eCollection 2014.
10
Purinergic signaling underlies CFTR control of human airway epithelial cell volume.嘌呤能信号传导是囊性纤维化跨膜传导调节因子(CFTR)控制人气道上皮细胞体积的基础。
J Cyst Fibros. 2004 Jun;3(2):99-117. doi: 10.1016/j.jcf.2004.01.006.

引用本文的文献

1
Viral and cellular insulators promote sustained HSV vector-mediated transgene expression in brain.病毒和细胞绝缘子促进单纯疱疹病毒载体介导的转基因在大脑中的持续表达。
Mol Ther. 2025 Apr 2;33(4):1420-1433. doi: 10.1016/j.ymthe.2025.02.039. Epub 2025 Feb 28.
2
Highly branched poly β-amino ester/CpG-depleted plasmid nanoparticles for non-viral gene therapy in lung cystic fibrosis disease.用于肺囊性纤维化疾病非病毒基因治疗的高度支化聚β-氨基酯/CpG缺失质粒纳米颗粒
Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101292. doi: 10.1016/j.omtm.2024.101292. eCollection 2024 Sep 12.
3
In Vivo Selection of S/MAR Sequences to Favour AAV Episomal Maintenance in Dividing Cells.

本文引用的文献

1
Genome-wide profiling of S/MAR-based replicon contact sites.基于S/MAR的复制子接触位点的全基因组分析。
Nucleic Acids Res. 2017 Jul 27;45(13):7841-7854. doi: 10.1093/nar/gkx522.
2
CRISPR/Cas9 - Mediated Precise Targeted Integration In Vivo Using a Double Cut Donor with Short Homology Arms.CRISPR/Cas9 介导的使用短同源臂双切口供体在体内进行精确靶向整合。
EBioMedicine. 2017 Jun;20:19-26. doi: 10.1016/j.ebiom.2017.05.015. Epub 2017 May 11.
3
Magnetofection Enhances Lentiviral-Mediated Transduction of Airway Epithelial Cells through Extracellular and Cellular Barriers.
在体内选择基质附着区域(S/MAR)序列以促进腺相关病毒(AAV)在分裂细胞中的游离型维持
Int J Mol Sci. 2024 Nov 27;25(23):12734. doi: 10.3390/ijms252312734.
4
Downregulation of epithelial sodium channel (ENaC) activity in cystic fibrosis cells by epigenetic targeting.通过表观遗传靶向下调囊性纤维化细胞中的上皮钠通道(ENaC)活性。
Cell Mol Life Sci. 2022 Apr 25;79(5):257. doi: 10.1007/s00018-022-04190-9.
5
Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy.非病毒、附加型载体在基因治疗中的开发和应用进展。
Hum Gene Ther. 2021 Oct;32(19-20):1076-1095. doi: 10.1089/hum.2020.310. Epub 2021 Sep 20.
6
DNA Methylation Patterns Correlate with the Expression of , , and (Epithelial Sodium Channel, ENaC) Genes.DNA甲基化模式与α、β、γ(上皮钠通道,ENaC)基因的表达相关。
Int J Mol Sci. 2021 Apr 4;22(7):3754. doi: 10.3390/ijms22073754.
7
-Beyerane Diterpenes as a Key Platform for the Development of ArnT-Mediated Colistin Resistance Inhibitors.贝叶烷二萜类化合物作为开发ArnT介导的黏菌素耐药抑制剂的关键平台
J Org Chem. 2020 Aug 21;85(16):10891-10901. doi: 10.1021/acs.joc.0c01459. Epub 2020 Aug 10.
8
A novel colistin adjuvant identified by virtual screening for ArnT inhibitors.一种新型多粘菌素助剂,通过虚拟筛选 ArnT 抑制剂发现。
J Antimicrob Chemother. 2020 Sep 1;75(9):2564-2572. doi: 10.1093/jac/dkaa200.
9
Episomal vectors based on S/MAR and the β-globin Replicator, encoding a synthetic transcriptional activator, mediate efficient γ-globin activation in haematopoietic cells.基于 S/MAR 和 β-珠蛋白复制子的附加体载体,编码一种合成转录激活因子,可有效介导造血细胞中 γ-珠蛋白的激活。
Sci Rep. 2019 Dec 24;9(1):19765. doi: 10.1038/s41598-019-56056-z.
10
TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy.TALEN 介导的囊性纤维化基因治疗的基因靶向。
Genes (Basel). 2019 Jan 11;10(1):39. doi: 10.3390/genes10010039.
磁转染通过细胞外和细胞屏障增强慢病毒介导的气道上皮细胞转导。
Genes (Basel). 2016 Nov 23;7(11):103. doi: 10.3390/genes7110103.
4
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.针对囊性纤维化患者的首次人体慢病毒试验的准备工作。
Thorax. 2017 Feb;72(2):137-147. doi: 10.1136/thoraxjnl-2016-208406. Epub 2016 Nov 16.
5
Genetic medicines for CF: Hype versus reality.用于囊性纤维化的基因药物:炒作与现实
Pediatr Pulmonol. 2016 Oct;51(S44):S5-S17. doi: 10.1002/ppul.23543.
6
Human airway epithelial cells investigated by atomic force microscopy: A hint to cystic fibrosis epithelial pathology.通过原子力显微镜研究的人气道上皮细胞:对囊性纤维化上皮病理学的一个提示。
Exp Cell Res. 2016 Oct 15;348(1):46-55. doi: 10.1016/j.yexcr.2016.08.025. Epub 2016 Aug 31.
7
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.依库珠单抗/ivacaftor 联合治疗对肺功能亚组纯合子 Phe508del CFTR 囊性纤维化患者的疗效和安全性:一项汇总分析。
Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.
8
Cystic fibrosis.囊性纤维化。
Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.
9
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.反复雾化非病毒 CFTR 基因治疗囊性纤维化患者:一项随机、双盲、安慰剂对照、2b 期试验。
Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.
10
A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis.从基因型角度看CFTR基因遗传学,凸显了囊性纤维化临床大类背后的特定突变模式。
Mol Med. 2015 Apr 21;21(1):257-75. doi: 10.2119/molmed.2014.00229.